The companies estimate there are at least 200,000 lupus patients in the U.S. who could benefit from the drug.
Analysts estimate the drug could reach annual sales exceeding $3 billion within five years.
How does this math make sense? $3 billion / 200,000 = $15,000. So (not counting sales outside the U.S.) they’re talking about each person paying fifteen grand per year for this drug alone. How do the economics of that make sense?
We have to figure out a way to bring drugs to market more efficiently. A phased rollout would let drugs come to market sooner and mitigate risk.